Table 4. irAEs Profile According to LIPI.
| All (N = 168) | Good (N = 82) | Intermediate (N = 73) | Poor (N = 13) | P overall | |
|---|---|---|---|---|---|
| Toxicity | 104 (61.9%) | 61 (74.4%) | 36 (49.3%) | 7 (53.8%) | 0.004 |
| Dermatological | |||||
| No | 142 (84.5%) | 69 (84.1%) | 62 (84.9%) | 11 (84.6%) | 1.000 |
| Yes | 26 (15.5%) | 13 (15.9) | 11 (15.1%) | 2 (15.4%) | 1.000 |
| Gastrointestinal | |||||
| No | 126 (75.0%) | 61 (74.4%) | 55 (75.3%) | 10 (76.9%) | 1.000 |
| Yes | 42 (25.0%) | 21 (25.6%) | 18 (24.7%) | 3 (23.1%) | 1.000 |
| Lung | |||||
| No | 152 (90.5%) | 72 (87.8%) | 68 (93.2%) | 12 (92.3%) | 0.520 |
| Yes | 16 (9.5%) | 10 (12.2%) | 5 (6.85%) | 1 (7.7%) | 0.520 |
| Endocrine | |||||
| No | 111 (66.1%) | 51 (62.2%) | 52 (71.2%) | 8 (61.5%) | 0.457 |
| Yes | 57 (33.9%) | 31 (37.8%) | 21 (28.8%) | 5 (38.5%) | 0.457 |
| Musculoeskeletal | |||||
| No | 147 (87.5%) | 71 (86.6%) | 64 (87.7%) | 12 (92.3%) | 1.000 |
| Yes | 21 (12.5%) | 11 (13.4%) | 9 (12.3%) | 1 (7.69%) | 1.000 |
| Renal | |||||
| No | 159 (94.6%) | 77 (93.9%) | 69 (94.5%) | 13 (100%) | 1.000 |
| Yes | 9 (5.4%) | 5 (6.1%) | 4 (5.5%) | 0 (0%) | 1.000 |
| Neurological | |||||
| No | 163 (97.0%) | 79 (96.3%) | 72 (98.6%) | 12 (92.3%) | 0.267 |
| Yes | 5 (3%) | 3 (3.7%) | 1 (1.4%) | 1 (7.7%) | 0.267 |
| Hematological | |||||
| No | 161 (96.4%) | 75 (92.6%) | 73 (100%) | 13 (100%) | 0.039 |
| Yes | 6 (3.6%) | 6 (7.4%) | 0 (0%) | 0 (0%) | 0.039 |
| Cardiovascular | |||||
| No | 161 (95.8%) | 76 (92.7%) | 72 (98.6%) | 13 (100%) | 0.196 |
| Yes | 7 (4.2%) | 6 (7.3%) | 1 (1.4%) | 0 (0%) | 0.196 |
| Ophthalmological | |||||
| No | 159 (94.6%) | 79 (96.3%) | 68 (93.2%) | 12 (92.3%) | 0.473 |
| Yes | 9 (5.4%) | 3 (3.7%) | 5 (6.8%) | 1 (7.3%) | 0.473 |
irAEs: immune-related adverse events; LIPI: lung immune prognostic index.